Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization

Cell Reports

Volumn 13, Issue 9, 2015, Pages 2014-2026

  Björnson, Elias ^a   Mukhopadhyay, Bani ^b   Asplund, Anna ^c   Pristovsek, Nusa ^c   Cinar, Resat ^b   Romeo, Stefano ^d,e,f   Uhlen, Mathias ^g   Kunos, George ^b   Nielsen, Jens ^a,g   Mardinoglu, Adil ^a,g  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^g ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Acetate; ACSS1; ACSS2; Genome scale metabolic models; Hepatocellular carcinoma; Proteome; Transcriptome

Indexed keywords

ACETATE COENZYME A LIGASE; ACETIC ACID; PROTEOME; TRANSCRIPTOME; ACETIC ACID DERIVATIVE; ACSS2 PROTEIN, HUMAN; FATTY ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; HETEROGENEOUS EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; STRATIFICATION; AGED; ALGORITHM; ANIMAL; BIOSYNTHESIS; FEMALE; GENETICS; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MITOCHONDRION; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ACETATE-COA LIGASE; ACETATES; AGED; ALGORITHMS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FATTY ACIDS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; MITOCHONDRIA; RNA, MESSENGER;

EID: 84947562163     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.10.045     Document Type: Article

References (54)

1. Agren R., Bordel S., Mardinoglu A., Pornputtapong N., Nookaew I., Nielsen J. Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput. Biol. 2012, 8:e1002518.
2. Agren R., Mardinoglu A., Asplund A., Kampf C., Uhlen M., Nielsen J. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol. Syst. Biol. 2014, 10:721.
3. Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11:R106.
4. Carracedo A., Cantley L.C., Pandolfi P.P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 2013, 13:227-232.
5. Cinar R., Godlewski G., Liu J., Tam J., Jourdan T., Mukhopadhyay B., Harvey-White J., Kunos G. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology 2014, 59:143-153.
6. Comerford S.A., Huang Z., Du X., Wang Y., Cai L., Witkiewicz A.K., Walters H., Tantawy M.N., Fu A., Manning H.C., et al. Acetate dependence of tumors. Cell 2014, 159:1591-1602.
7. Dai Y., Liu L., Zeng T., Zhu Y.H., Li J., Chen L., Li Y., Yuan Y.F., Ma S., Guan X.Y. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2013, 436:711-718.
8. Dongiovanni P., Donati B., Fares R., Lombardi R., Mancina R.M., Romeo S., Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World J. Gastroenterol. 2013, 19:6969-6978.
9. Dongiovanni P., Petta S., Maglio C., Fracanzani A.L., Pipitone R., Mozzi E., Motta B.M., Kaminska D., Rametta R., Grimaudo S., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2014, 61:506-514.
10. Eddy J.A., Hood L., Price N.D., Geman D. Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC). PLoS Comput. Biol. 2010, 6:e1000792.
11. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012, 56:908-943. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of CancerEuropean Organisation For Research And Treatment Of Cancer.
12. Fagerberg L., Hallström B.M., Oksvold P., Kampf C., Djureinovic D., Odeberg J., Habuka M., Tahmasebpoor S., Danielsson A., Edlund K., et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteomics 2014, 13:397-406.
13. Folger O., Jerby L., Frezza C., Gottlieb E., Ruppin E., Shlomi T. Predicting selective drug targets in cancer through metabolic networks. Mol. Syst. Biol. 2011, 7:501.
14. Gatto F., Nookaew I., Nielsen J. Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma. Proc. Natl. Acad. Sci. USA 2014, 111:E866-E875.
15. Ghaffari P., Mardinoglu A., Asplund A., Shoaie S., Kampf C., Uhlen M., Nielsen J. Identifying anti-growth factors for human cancer cell lines through genome-scale metabolic modeling. Sci. Rep. 2015, 5:8183.
16. Herzig S., Raemy E., Montessuit S., Veuthey J.L., Zamboni N., Westermann B., Kunji E.R., Martinou J.C. Identification and functional expression of the mitochondrial pyruvate carrier. Science 2012, 337:93-96.
17. Kampf C., Mardinoglu A., Fagerberg L., Hallström B.M., Edlund K., Lundberg E., Pontén F., Nielsen J., Uhlen M. The human liver-specific proteome defined by transcriptomics and antibody-based profiling. FASEB J. 2014, 28:2901-2914.
18. Kampf C., Mardinoglu A., Fagerberg L., Hallström B.M., Danielsson A., Nielsen J., Pontén F., Uhlen M. Defining the human gallbladder proteome by transcriptomics and affinity proteomics. Proteomics 2014, 14:2498-2507.
19. Le A., Lane A.N., Hamaker M., Bose S., Gouw A., Barbi J., Tsukamoto T., Rojas C.J., Slusher B.S., Zhang H., et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012, 15:110-121.
20. Le Foll B., Gorelick D.A., Goldberg S.R. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl.) 2009, 205:171-174.
21. Lewis N.E., Abdel-Haleem A.M. The evolution of genome-scale models of cancer metabolism. Front. Physiol. 2013, 4:237.
22. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390. SHARP Investigators Study Group.
23. Luo D., Wang Z., Wu J., Jiang C., Wu J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. BioMed Res. Int. 2014, 2014:409272.
24. Mardinoglu A., Nielsen J. Systems medicine and metabolic modelling. J. Intern. Med. 2012, 271:142-154.
25. Mardinoglu A., Nielsen J. New paradigms for metabolic modeling of human cells. Curr. Opin. Biotechnol. 2015, 34:91-97.
26. Mardinoglu A., Agren R., Kampf C., Asplund A., Nookaew I., Jacobson P., Walley A.J., Froguel P., Carlsson L.M., Uhlen M., Nielsen J. Integration of clinical data with a genome-scale metabolic model of the human adipocyte. Mol. Syst. Biol. 2013, 9:649.
27. Mardinoglu A., Gatto F., Nielsen J. Genome-scale modeling of human metabolism - a systems biology approach. Biotechnol. J. 2013, 8:985-996.
28. Mardinoglu A., Agren R., Kampf C., Asplund A., Uhlen M., Nielsen J. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nat. Commun. 2014, 5:3083.
29. Mardinoglu A., Heiker J.T., Gärtner D., Björnson E., Schön M.R., Flehmig G., Klöting N., Krohn K., Fasshauer M., Stumvoll M., et al. Extensive weight loss reveals distinct gene expression changes in human subcutaneous and visceral adipose tissue. Sci. Rep. 2015, 5:14841.
30. Mashimo T., Pichumani K., Vemireddy V., Hatanpaa K.J., Singh D.K., Sirasanagandla S., Nannepaga S., Piccirillo S.G., Kovacs Z., Foong C., et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 2014, 159:1603-1614.
31. Metallo C.M., Gameiro P.A., Bell E.L., Mattaini K.R., Yang J., Hiller K., Jewell C.M., Johnson Z.R., Irvine D.J., Guarente L., et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481:380-384.
32. Mukhopadhyay B., Schuebel K., Mukhopadhyay P., Cinar R., Godlewski G., Xiong K., Mackie K., Lizak M., Yuan Q., Goldman D., Kunos G. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology 2015, 61:1615-1626.
33. Mullen A.R., Wheaton W.W., Jin E.S., Chen P.H., Sullivan L.B., Cheng T., Yang Y., Linehan W.M., Chandel N.S., DeBerardinis R.J. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012, 481:385-388.
34. O'Brien E.J., Monk J.M., Palsson B.O. Using genome-scale models to predict biological capabilities. Cell 2015, 161:971-987.
35. Oberhardt M.A., Yizhak K., Ruppin E. Metabolically re-modeling the drug pipeline. Curr. Opin. Pharmacol. 2013, 13:778-785.
36. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., Harvey-White J., Mackie K., Offertáler L., Wang L., Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 2005, 115:1298-1305.
37. Osei-Hyiaman D., Liu J., Zhou L., Godlewski G., Harvey-White J., Jeong W.I., Bátkai S., Marsicano G., Lutz B., Buettner C., Kunos G. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest. 2008, 118:3160-3169.
38. Patil K.R., Nielsen J. Uncovering transcriptional regulation of metabolism by using metabolic network topology. Proc. Natl. Acad. Sci. USA 2005, 102:2685-2689.
39. Schug Z.T., Peck B., Jones D.T., Zhang Q., Grosskurth S., Alam I.S., Goodwin L.M., Smethurst E., Mason S., Blyth K., et al. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 2015, 27:57-71.
40. Shoaie S., Nielsen J. Elucidating the interactions between the human gut microbiota and its host through metabolic modeling. Front. Genet. 2014, 5:86.
41. Tam J., Cinar R., Liu J., Godlewski G., Wesley D., Jourdan T., Szanda G., Mukhopadhyay B., Chedester L., Liow J.S., et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012, 16:167-179.
42. Tanaka M., Masaki Y., Tanaka K., Miyazaki M., Kato M., Sugimoto R., Nakamura K., Aishima S., Shirabe K., Nakamuta M., et al. Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC. Mol. Med. Rep. 2013, 7:365-370.
43. Uhlén M., Oksvold P., Fagerberg L., Lundberg E., Jonasson K., Forsberg M., Zwahlen M., Kampf C., Wester K., Hober S., et al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol. 2010, 28:1248-1250.
44. Uhlén M., Fagerberg L., Hallström B.M., Lindskog C., Oksvold P., Mardinoglu A., Sivertsson Å., Kampf C., Sjöstedt E., Asplund A., et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347:1260419.
45. Väremo L., Nielsen J., Nookaew I. Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods. Nucleic Acids Res. 2013, 41:4378-4391.
46. Väremo L., Scheele C., Broholm C., Mardinoglu A., Kampf C., Asplund A., Nookaew I., Uhlén M., Pedersen B.K., Nielsen J. Proteome- and transcriptome-driven reconstruction of the human myocyte metabolic network and its use for identification of markers for diabetes. Cell Rep. 2015, 11:921-933.
47. Vāvere A.L., Kridel S.J., Wheeler F.B., Lewis J.S. 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J. Nucl. Med. 2008, 49:327-334.
48. Wellen K.E., Hatzivassiliou G., Sachdeva U.M., Bui T.V., Cross J.R., Thompson C.B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009, 324:1076-1080.
49. Yizhak K., Gaude E., Le Dévédec S., Waldman Y.Y., Stein G.Y., van de Water B., Frezza C., Ruppin E. Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer. eLife 2014, 3:e03641.
50. Yizhak K., Chaneton B., Gottlieb E., Ruppin E. Modeling cancer metabolism on a genome scale. Mol. Syst. Biol. 2015, 11:817.
51. Yoshii Y., Waki A., Furukawa T., Kiyono Y., Mori T., Yoshii H., Kudo T., Okazawa H., Welch M.J., Fujibayashi Y. Tumor uptake of radiolabeled acetate reflects the expression of cytosolic acetyl-CoA synthetase: implications for the mechanism of acetate PET. Nucl. Med. Biol. 2009, 36:771-777.
52. Yoshimoto M., Waki A., Yonekura Y., Sadato N., Murata T., Omata N., Takahashi N., Welch M.J., Fujibayashi Y. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl. Med. Biol. 2001, 28:117-122.
53. Yun M., Bang S.H., Kim J.W., Park J.Y., Kim K.S., Lee J.D. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J. Nucl. Med. 2009, 50:1222-1228.
54. Zhu Y., Qiu P., Ji Y. TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat. Methods 2014, 11:599-600.